PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Net income growth under 50% of GNPX's 37.08%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
720.76%
D&A growth well above GNPX's 42.70%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Some yoy growth while GNPX is negative at -100.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-18.24%
Both cut yoy SBC, with GNPX at -67.58%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-114.66%
Negative yoy working capital usage while GNPX is 96.38%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Negative yoy AP while GNPX is 76.59%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
139.41%
Some yoy usage while GNPX is negative at -99.98%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-139.67%
Negative yoy while GNPX is 98.70%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-28.06%
Negative yoy CFO while GNPX is 20.37%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-383.87%
Negative yoy CapEx while GNPX is 79.13%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
We reduce yoy invests while GNPX stands at 79.13%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Both yoy lines negative, with GNPX at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.